One research institute leads the ranked assignee list with 21 of the 32 records in this dataset, a considerable margin over the rest of the field — fifth place holds only 2 records. The gap suggests the field has one dominant early filer rather than several competing portfolios of similar size. Most other organisations in the ranking, which covers 21 companies in total, appear with just one or two records, typical of an area still being explored rather than consolidated.

The claims in this dataset centre on converting biological signal into measurable format — for example recoding amino-acid polymer sequence into DNA polymers, or barcoding macromolecules inside individual cells — and on reconciling sparse, multi-modal readouts across tissue sections. Classification data shows G01N (material analysis and testing) and C12Q (enzyme/DNA-based measurement) covering the majority of the 32 records, with smaller shares in combinatorial chemistry libraries, bioinformatics and medicinal preparations. This points to an assay-mechanics-heavy field rather than a purely computational one.

Filing volume in this dataset was negligible in the earlier years covered (2017 onward) and rose to a peak of 17 records in 2023, the highest single year on record here. Because patent publication typically lags filing by around 18 months, the most recent year or two in any such trend will understate actual filing activity, so 2023 may not remain the true peak once later filings publish. There are too few complete years after accounting for that lag to state a reliable growth rate.